CATO SMS announces acquisition of Wilmington-based Array Biostatistics
Category: #headline  By Mateen Dalal  Date: 2020-09-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

CATO SMS announces acquisition of Wilmington-based Array Biostatistics

CATO SMS, one of the leading providers of specialized clinical research solutions, has reportedly acquired Array Biostatistics LLC, a full service statistical and biostatistical programming CRO, in a bid to expand its service portfolio. The company is planning to invest in Array and its renowned biostatistical capabilities.

Sources cite that the acquisition will help CATO SMS to scale its full-service biostatistical analysis, consulting, and programming capabilities. The deal will also help the company to improve the capabilities of its team of statistical programmers and biostaticians, as it continues to expand its clinical research solutions. Array CEO Sandy Ferber will continue to lead the company and will also spearhead CATO SMS’ biometrics offers.  

Speaking on the acquisition, Mr. Ferber said that the company is thrilled to have this opportunity to expand the company’s biostatical offering in a partnership with CATO SMS. Both companies share similar values centered on high-quality and a commitment to offering their clients with highly tailored services.

Mr. Ferber added that the deal has enabled the company to provide its clients with enhanced capabilities in several areas.

Mark A. Goldberg, M.D., exec chairman of CATO SMS said that the acquisition furthers the company’s goal of offering its clients with a complete portfolio of specialized solutions to efficiently support the development of drugs in challenging therapeutic areas including rare and orphan indications, oncology, and cell and gene therapy, etc.

The deal marks an advancement in CATO SMS' strategic expansion. The company was established in 2019 with the merger of SMS-oncology and Cato Research. Since then, the companies have been putting their best foot forward to expand global footprint, deepen regulatory and oncology expertise, and strengthen the suite of solutions.

The company has offices in Europe, North America, and Middle East and conducts clinical trials in over 20 nations. To date, the firm has contributed to the development of over 50 marketed products.

Source Credit - https://www.prnewswire.com/news-releases/cato-sms-acquires-array-biostatistics-301130794.html

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Coherent’s shares surge by 33% after Lumentum reveals acquisition plans
Coherent’s shares surge by 33% after Lumentum reveals acquisition plans
By Mateen Dalal

Coherent Inc., an American leading provider of lasers and laser-based technologies, witnessed a 33% ...

Mercedes Benz India planning to launch 15 new vehicles in 2021
Mercedes Benz India planning to launch 15 new vehicles in 2021
By Mateen Dalal

According to reliable sources, luxury car manufacturer Mercedes Benz India Pvt. Ltd. is planning on ...

AltPep Corporation raises USD 23.15 million in Series A funding round
AltPep Corporation raises USD 23.15 million in Series A funding round
By Mateen Dalal

According to reliable sources, U.S.-based privately held biomedical organization AltPep Corporation ...